Payment overview · 2025
General Payments
$1,129.18
55 reported records · 18 companies
Healthcare provider profile · identity verified
James A. Loomis, MD
Allopathic & Osteopathic Physicians|Family Medicine · LIVERPOOL, NY · NPI 1790006294
Verified facts
What the public records show
CMS Open Payments records show James A. Loomis, MD received $1,129.18 in general payments during 2025 across 55 reported records.
ABBVIE INC. accounted for 12.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $139.74 | 12.4% | 9 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $137.42 | 12.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $129.13 | 11.4% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $98.37 | 8.7% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.64 | 7.6% | 5 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $81.11 | 7.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.57 | 6.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $67.66 | 6.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $56.07 | 5.0% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $48.60 | 4.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.46 | 4.1% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $37.77 | 3.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.28 | 3.3% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $26.69 | 2.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.61 | 1.7% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.64 | 1.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $15.83 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.59 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,129.18 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $139.74 | 9 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $137.42 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $129.13 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $98.37 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $83.12 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $81.72 | 5 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $81.11 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.57 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $71.57 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $70.00 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $67.66 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $56.07 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.53 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $48.60 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.28 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.89 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 124 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 17 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1013 | 273 |
| Lisinopril | Lisinopril | 659 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 502 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 423 | 97 |
| Omeprazole | Omeprazole | 415 | 92 |
| Losartan Potassium | Losartan Potassium | 342 | 90 |
| Metformin Hcl | Metformin Hcl | 341 | 89 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 329 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 307 | 82 |
| Simvastatin | Simvastatin | 246 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 71 |
| Gabapentin | Gabapentin | 207 | 55 |
| Sertraline Hcl | Sertraline Hcl | 206 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 57 |
| Trazodone Hcl | Trazodone Hcl | 196 | 53 |
| Famotidine | Famotidine | 180 | 53 |
| Metformin Hcl Er | Metformin Hcl | 177 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 172 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 167 | 45 |
| Allopurinol | Allopurinol | 132 | 34 |
| Alprazolam | Alprazolam | 127 | 26 |
| Ozempic | Semaglutide | 125 | 24 |
| Eliquis | Apixaban | 124 | 32 |
| Furosemide | Furosemide | 123 | 36 |
| Montelukast Sodium | Montelukast Sodium | 119 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 108 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 33 |
| Prednisone | Prednisone | 89 | 46 |
| Jardiance | Empagliflozin | 87 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 17 |
| Glipizide Er | Glipizide | 75 | 21 |
| Clonazepam | Clonazepam | 74 | suppressed |
| Meloxicam | Meloxicam | 70 | 17 |
| Potassium Chloride | Potassium Chloride | 70 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | suppressed |
| Carvedilol | Carvedilol | 69 | 18 |
| Ramipril | Ramipril | 68 | 17 |
| Fenofibrate | Fenofibrate | 65 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 15 |
| Ondansetron Odt | Ondansetron | 63 | 14 |
| Alendronate Sodium | Alendronate Sodium | 62 | 16 |
| Buspirone Hcl | Buspirone Hcl | 61 | 14 |
| Topiramate | Topiramate | 61 | 12 |
| Ibuprofen | Ibuprofen | 60 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 13 |
| Doxepin Hcl | Doxepin Hcl | 52 | 12 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 29 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 12 |
| Januvia | Sitagliptin Phosphate | 49 | 12 |
| Spironolactone | Spironolactone | 48 | 15 |
| Synthroid | Levothyroxine Sodium | 47 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 12 |
| Ezetimibe | Ezetimibe | 44 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 11 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Glipizide | Glipizide | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 35 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | suppressed |
| Baclofen | Baclofen | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 13 |
| Nystatin | Nystatin | 38 | 13 |
| Azithromycin | Azithromycin | 37 | 34 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Atenolol | Atenolol | 35 | 11 |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | 11 |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Finasteride | Finasteride | 30 | 11 |
| Glimepiride | Glimepiride | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 27 |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 24 |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | 11 |
| Fluconazole | Fluconazole | 20 | 17 |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 13 |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,129.18 · 55 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, BREZTRI, CAPLYTA, CRYSVITA, Cologuard Collection Kit, ELIQUIS, INSPIRE, Korlym, MOUNJARO, NURTEC ODT, Omnipod, Ozempic, QULIPTA, REZDIFFRA, Rybelsus, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Veozah, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error